Anderson CP, Tsai JM, Chan WW, Park CK, Liu RM, Forman HJ, Reynolds CP: Buthionine sulfoximine is cytotoxic via apoptosis and synergistically enhances the activity of melphalan in human neuroblastoma cell lines. Proceedings of 32th Annual Meeting , Amer. Soc. Clin. Oncol, 1996. (abstract).
Anderson CP, Tsai JM, Chan WW, Park CK, Liu RM, Forman HJ, Reynolds CP: Buthionine sulfoximine is cytotoxic and enhances the activity of melphalan for human neuroblastoma cell lines. Advances in Neuroblastoma Research 1996, Philadelphia, PA. (oral presentation of abstract).
Anderson CP, Nandy P, Periclou A, Avramis VI: Pharmacodynamic (PD) modeling studies of cytarabine (ara-c) in pediatric leukemia patients. Medical and Pediatric Oncology, 29(5):336, 1997. (oral presentation of abstract).
Anderson CP, Seeger RC, Matthay KK, et al.: A phase I trial of buthionine sulfoximine in combination with melphalan for children with recurrent neuroblastoma. Advances in Neuroblastoma Research 1998, Bath, UK (oral presentation of abstract).
Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Proceedings of 34th Annual Meeting , Amer. Soc. Clin. Oncol 17: 531a, 1998. (abstract).
Anderson CP, Castro CS, Meeks WM, Satake N, Reynolds CP: Physiologic bone marrow oxygen tension (O2T) contributes to buthionine sulfoximine (BSO) resistance in neuroblastoma. Medical and Pediatric Oncology, 33(3):266, 1999. (abstract).
Anderson CP, Seeger RC, Matthay KK, et al.: Buthionine sulfoximine alone and in combination with melphalan is active against recurrent neuroblastoma. Medical and Pediatric Oncology, 33(3):158, 1999. (oral presentation of abstract).
Anderson CP, Keshelava N, Meeks WH, Satake N, Reynolds CP: Buthionine sulfoximine (BSO) synergizes the action of melphalan (L-PAM) for neuroblastoma cell lines established after disease progression in intensively treated patients. Advances in Neuroblastoma Research 2000, Philadelphia, PA. (oral presentation of abstract).
Anderson CP, Castro CS, Meeks WM, Satake N, Reynolds CP: Physiologic bone marrow oxygen tension (O2T) contributes to buthionine sulfoximine (BSO) resistance in neuroblastoma. General Clinical Research Center National Meeting, Washington, D.C., March 2001.
Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Proceedings of 38th Annual Meeting, Amer. Soc. Clin. Oncol 21:398a, 2002.
Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP: Pilot study of buthionine sulfoximine and melphalan in children with recurrent neuroblastoma. Advances in Neuroblastoma Research 2002, Paris, France.
Bo.Yang, Nino Kelshelava, Clarke P. Anderson and C. Patrick Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia is Reversed by the Bioreductive Agent Tirapazamine Advances in Neuroblastoma Research 2002, Paris, France.
M.E. Estany, K. McGinty, and Anderson CP. The use of Reiki as a complementary therapy for pediatric palliative care, 8th European Association Palliative Care, Den Hague, 2003.
Lambrecht T and Anderson CP. Multidisciplinary Survey of Pediatric Palliative Care: Attitudes and Experience in a Large Metropolitan Pediatric Hospital. 8th European Association Palliative Care, Den Hague, 2003 (received award for best abstract).
Lambrecht T and Anderson CP. Multidisciplinary attitudes toward cultural and spiritual beliefs In pediatric palliative care. 8th European Association Palliative Care, Den Hague, 2003.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 06/08.